Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 481 participants.

Also called NCT02928497

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 481 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02928497
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Czechia, Denmark, Germany, Italy, Netherlands, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02928497. Randomized; no masking; primary purpose prevention. Start 2017-02-06 (actual); primary completion 2025-09-23 (actual). Results posted on 2026-08-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
Acronym
ASAP-TOO
Condition
Stroke
Intervention (Device)
WATCHMAN LAAC Device Implant
Intervention (Drug)
Single Antiplatelet Therapy or No Therapy (Control)
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct02928497
Content hash
b7e2eea181562188b41e565cea26730a6f7f5e2035256253770397e4ed255df9